Trial Profile

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMXT 1501 (Primary) ; Eflornithine (Primary)
Indications Glioma
Focus First in man; Therapeutic Use

Most Recent Events

24 Oct 2025 Planned number of patients changed from 15 to 18.
29 Aug 2023 Planned End Date changed from 15 Jan 2026 to 15 Sep 2027.
29 Aug 2023 Planned primary completion date changed from 15 Jan 2025 to 15 Jan 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com